Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy

Siebenhaar, Frank; Kühn, W; Zuberbier, Torsten; Maurer, Marcus

doi:10.1016/j.jaci.2007.05.011

Cited by 55 publications

(40 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In accordance with previous findings in four case reports in the literature comprising 5 patients (8)(9)(10)(11)) the present data demonstrate that omalizumab application is an effective treatment for systemic mast cell activation disease. Omalizumab reversibly binds to the Fc portion of the IgE molecule, thereby forming small, biologically inert, noncomplementfixing complexes which are cleared with a terminal half-life of 26 days [for review on its pharmacokinetics, see (12)].…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases

et al. 2011

View full text Add to dashboard Cite

We report on the outcome of 4 patients with therapy-resistant systemic mast cell activation disease (MCAD) treated with the anti-IgE monoclonal antibody omalizumab in compassionate use. Two patients achieved an impressive persistent clinical response to treatment with omalizumab. In the third patient symptoms gradually improved. In the fourth patient omalizumab treatment had to be discontinued due to intolerable mast cell mediator-induced symptoms. In conclusion, omalizumab can lessen the intensity of the symptoms of systemic MCAD. Hence, omalizumab should be considered as a therapeutic option in cases of systemic MCAD that are resistant to evidence-based therapy.

show abstract

Section: Discussionsupporting

confidence: 93%

“…In the previous case reports, serum tryptase was reported to decrease under omalizumab therapy in two mastocytosis patients (8,9) but it remained unchanged in two other patients (5). In the present patients we observed a decline of the mast cell mediators tryptase and methylhistamine, respectively, in two of them.…”

Section: Discussionsupporting

confidence: 64%

Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Systemische Therapien mit Glukokortikoiden oder Tyrosinkinaseinhibitoren bleiben den schweren Formen der kindlichen Mastozytose vorbehalten [5,15]. Experimentelle Therapien, die in der Behandlung symptomatischer kutaner Mastozytosen als wirksam beschrieben sind, wie beispielsweise der Einsatz von Anti-IgE-Antikörpern, finden bislang kaum Anwendung im Kindesalter [23]. Da bestehende Typ-I-Sensibilisierungen in Verbindung mit Mastozytosen das Risiko für schwere anaphylaktische Reaktionen erhöhen, sollten bei Verdacht spezifische diagnostische Maß-nahmen ergriffen werden.…”

Section: Therapieunclassified

Mastozytosen im Kindesalter

et al. 2012

View full text Add to dashboard Cite

Mastocytoses are a group of rare diseases characterized, in most cases, by a benign proliferation and accumulation of mast cells in different tissues. In children, mastocytosis affects usually exclusively the skin and differs in many aspects from adult-onset mastocytosis. Except for diffuse cutaneous mastocytosis, which is an uncommon subtype of childhood-onset mastocytosis, involvement of the bone marrow or additional extracutaneous organs is rarely seen in children. The prognosis of childhood-onset mastocytosis is usually very good. Compared to adult patients who most commonly experience chronic-stable or slowly progressive disease, mastocytosis in children is mostly transient and self-limiting. In this review, we present and discuss the subtypes of childhood-onset mastocytosis, recent advances in the understanding of their pathogenesis as well as similarities and differences between adult- and childhood-onset mastocytosis.

show abstract

“…Another emerging treatment approach in patients with mastocytosis and secondary IgE-dependent MCAS may be IgE depletion. In fact, it has been described in anecdotal cases that IgE depletion with omalizumab is effective in suppressing the symptoms of anaphylaxis in such patients [96][97][98][99]. However, omalizumab itself can cause anaphylaxis, and no data from controlled clinical trials are available.…”

Section: Novel Treatment Conceptsmentioning

confidence: 99%